Dimerix (ASX:DXB) share price soars as boss looks back on 'pivotal' year

It was a big FY21 for Dimerix. Here's what its CEO has to say about it.

| More on:
A health worker wearing disposable gloves holds a vial, treating a patient.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Dimerix Ltd (ASX: DXB) share price is taking off today. Meanwhile, the company has conducted its annual general meeting (AGM).

At the meeting, CEO Dr Nina Webster looked back on a year she described as "pivotal for the future of Dimerix".

Webster also stated she expects the drug discovery company will begin to glide through the final stages of development and towards profitability.

While Webster's comments weren't released to the public until mid-afternoon, the Dimerix share price has been soaring since this morning.

At market close on Monday, shares in the company finished at 33 cents apiece. That represents a 6.45% gain on their previous closing price.

Let's take a look at the year that's been for Dimerix and what Webster believes the future will hold.

Dimerix's boss on a successful FY21

The Dimerix share price is in the green today, the same day the company presented its AGM.  

In the meeting, Webster pointed to the achievements the company made over financial year 2021.

These included 2 clinical studies in which the company's lead drug candidate, DMX-200, treated COVID-19 patients.

The company also prepared for another phase 3 study into using DMX-200 to treat focal segmental glomerulosclerosis (FSGS).

With numerous drugs in the final stage of trials, Webster noted the company's portfolio is positioned for growth with commercial potential.

Webster also noted that, while much of the global population is, or soon will be, vaccinated against COVID-19, there will still be a need for treatments against the virus.

Additionally, drugs that can treat severe COVID-19 have typically been more expensive than other similar drugs. This has provided DMX-200 with an attractive market.

Finally, Dimerix finished FY21 under budget.

The company is now looking forward to providing guidance for all its near-term propositions, including the FSGS phase 3 program and its 2 COVID-19 clinical studies.

Dimerix is also engaging with potential licensing partners with the aim to provide the best outcome for its patients and shareholders.

It's also building alliances with others in commercial, clinical and manufacturing areas to enhance its chances for success.

Dimerix share price snapshot

Today's included, the Dimerix share price has gained 35% so far this year.

It is also 30% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »